Oruka Therapeutics, Inc. (ORKA) stock
ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
$95.81−1.76 (-1.80%)
Close on Nov 20, 2026Market cap $6.34BP/E –Yield –
Oruka Therapeutics shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Oruka Therapeutics's shares outstanding was 42M at Jun 30, 2025. For fiscal 2023 it was 14M, up 0.0% from the year before. Over ten years it grew 70.7% a year on average. The highest annual figure on record is 14M in fiscal 2023.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 14M | +0.0% |
| FY2022 | Dec 31, 2022 | 14M | +3.6% |
| FY2021 | Dec 31, 2021 | 14M | +195.2% |
| FY2020 | Dec 31, 2020 | 5M | +256.5% |
| FY2019 | Dec 31, 2019 | 1M | +71.7% |
| FY2018 | Dec 31, 2018 | 1M | +32.8% |
| FY2017 | Dec 31, 2017 | 1M | +15.0% |
| FY2016 | Dec 31, 2016 | 1M | +44.2% |
| FY2015 | Dec 31, 2015 | 0M | +114.7% |
| FY2014 | Dec 31, 2014 | 0M | +137.6% |
| FY2013 | Dec 31, 2013 | 0M | +288.1% |
| FY2012 | Dec 31, 2012 | 0M | +32.9% |
| FY2011 | Dec 31, 2011 | 0M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | 42M | +190.3% |
| Q1 FY2025 | Mar 31, 2025 | 42M | +188.8% |
| Q3 FY2024 | Sep 30, 2024 | 15M | +4.2% |
| Q2 FY2024 | Jun 30, 2024 | 3M | -77.8% |
| Q1 FY2024 | Mar 31, 2024 | 15M | +0.6% |
| Q4 FY2023 | Dec 31, 2023 | 14M | +0.2% |
| Q3 FY2023 | Sep 30, 2023 | 14M | 0.0% |
| Q2 FY2023 | Jun 30, 2023 | 14M | 0.0% |
| Q1 FY2023 | Mar 31, 2023 | 14M | 0.0% |
| Q4 FY2022 | Dec 31, 2022 | 14M | -0.0% |
| Q3 FY2022 | Sep 30, 2022 | 14M | 0.0% |
| Q2 FY2022 | Jun 30, 2022 | 14M | 0.0% |
| Q1 FY2022 | Mar 31, 2022 | 14M | +16.6% |
| Q4 FY2021 | Dec 31, 2021 | 14M | +53.7% |
| Q3 FY2021 | Sep 30, 2021 | 14M | +804.0% |
| Q2 FY2021 | Jun 30, 2021 | 14M | +802.3% |
| Q1 FY2021 | Mar 31, 2021 | 12M | +712.3% |
| Q4 FY2020 | Dec 31, 2020 | 9M | +642.0% |
| Q1 FY2020 | Mar 31, 2020 | 2M | +77.9% |
| Q4 FY2019 | Dec 31, 2019 | 2M | +106.4% |
| Q3 FY2019 | Sep 30, 2019 | 2M | +96.7% |
| Q2 FY2019 | Jun 30, 2019 | 1M | +63.4% |
| Q1 FY2019 | Mar 31, 2019 | 1M | +18.4% |
| Q4 FY2018 | Dec 31, 2018 | 1M | +18.2% |
| Q3 FY2018 | Sep 30, 2018 | 1M | +21.0% |
| Q2 FY2018 | Jun 30, 2018 | 1M | +49.3% |
| Q1 FY2018 | Mar 31, 2018 | 1M | +49.8% |
| Q4 FY2017 | Dec 31, 2017 | 1M | +29.7% |
| Q3 FY2017 | Sep 30, 2017 | 1M | +26.8% |
| Q2 FY2017 | Jun 30, 2017 | 1M | +2.9% |
| Q1 FY2017 | Mar 31, 2017 | 1M | – |
| Q4 FY2016 | Dec 31, 2016 | 1M | – |
| Q3 FY2016 | Sep 30, 2016 | 1M | – |
| Q2 FY2016 | Jun 30, 2016 | 1M | – |
See a number that looks wrong?